Bailard Inc. Boosts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Bailard Inc. increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.1% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 13,422 shares of the biopharmaceutical company’s stock after purchasing an additional 1,236 shares during the period. Bailard Inc.’s holdings in Regeneron Pharmaceuticals were worth $9,561,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. State Street Corp raised its stake in Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after acquiring an additional 61,277 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Regeneron Pharmaceuticals by 1.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock valued at $707,759,000 after acquiring an additional 11,499 shares during the last quarter. Swiss National Bank raised its stake in Regeneron Pharmaceuticals by 0.6% during the 3rd quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company’s stock valued at $338,079,000 after acquiring an additional 2,000 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its stake in Regeneron Pharmaceuticals by 0.4% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 302,616 shares of the biopharmaceutical company’s stock valued at $215,562,000 after acquiring an additional 1,108 shares during the last quarter. Finally, National Pension Service raised its stake in Regeneron Pharmaceuticals by 4.0% during the 4th quarter. National Pension Service now owns 232,450 shares of the biopharmaceutical company’s stock valued at $165,581,000 after acquiring an additional 8,833 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $698.74 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The stock has a fifty day moving average of $698.51 and a two-hundred day moving average of $868.16. The company has a market capitalization of $76.39 billion, a price-to-earnings ratio of 18.25, a PEG ratio of 2.34 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals’s revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $11.86 earnings per share. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.50%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Analyst Upgrades and Downgrades

REGN has been the subject of several analyst reports. Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th. BMO Capital Markets reduced their price objective on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research note on Tuesday, February 4th. Wolfe Research began coverage on Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 target price on the stock. UBS Group cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Finally, TD Cowen dropped their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.